An update on the treatment options for HBV/HCV coinfection

References

• Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562–1569.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Sagnelli C, Pisaturo M, et al. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenetrol. 2014;20(24):7635–7643.
   PubMed Web of Science ®Google Scholar
• Coppola N, Alessio L, Gualdieri L, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill. 2015;20(35):30009.
   PubMedGoogle Scholar
• Crespo J, Lozano JL, de la Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994;89:1147–1151.
   PubMed Web of Science ®Google Scholar
• Di Marco V, Lo Iacono O, Cammà C, et al. The long-term course of chronic hepatitis B. Hepatology. 1999;30:257–264.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Tagger A, Brollo L, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163:400–402.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Stroffolini T, Mele A, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012;18(14):1616–1621.
   PubMed Web of Science ®Google Scholar
• Ohkawa K, Hayashi N, Yuki N, et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol. 1994;21:509–514.
   PubMed Web of Science ®Google Scholar
• Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001;16:636–640.
   PubMed Web of Science ®Google Scholar
• Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51:759–766.
   PubMed Web of Science ®Google Scholar
• Pallás JR, Fariñas-Alvarez C, Prieto D, et al. Co-infections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999;15:699–704.
   PubMed Web of Science ®Google Scholar
• Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation. 2005;79(9):1132–1136.
   PubMed Web of Science ®Google Scholar
• Zhou J, Dore GJ, Zhang F, et al. TREAT Asia HIV observational database. Hepatitis B and C virus co-infection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol. 2007;22:1510–1518.
   PubMed Web of Science ®Google Scholar
• Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36(7):2084–2086.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in HCV chronic carriers, viral interaction and clinical course. Hepatology. 2002;36:1285–1291.
   PubMed Web of Science ®Google Scholar
• Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404–410.
   PubMed Web of Science ®Google Scholar
• Filippini P, Coppola N, Pisapia R, et al. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol. 2007;79(11):1679–1685.
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Tonziello G, et al. Virological pattern in three compartments (plasma, PBMC and liver tissue) and clinical outcome in chronic HBV/HCV coinfection. Antivir Ther. 2008;13:307–318.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients. Hepatology. 2006;1:99–106.
   Google Scholar
• Sheen IS, Liaw YF, Lin DY, et al. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis. 1994;170:358–361.
   PubMed Web of Science ®Google Scholar
• Zampino R, Marrone A, Merola A, et al. Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. J Med Virol. 2009;81:2012–2020.
   PubMed Web of Science ®Google Scholar
• Benvegnù L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994;74:2442–2448.
   PubMed Web of Science ®Google Scholar
• Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA. 1991;265:1974–1976.
   PubMed Web of Science ®Google Scholar
• Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347–354.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004;32:144–148.
   PubMed Web of Science ®Google Scholar
• Amin J, Dore GJ, O’Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community based linkage study. J Hepatol. 2006;45:197–203.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol. 2006;35(3):317–320.
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Disease, and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. [cited 2017 Sept 21]. Available from: http://hcvguidelines.org/sites/default/files/HCVGuidance_October_2016_a.pdf
   Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol. 2017 Jan;66(1):153–194. DOI:10.1016/j.jhep.2016.09.001
   Google Scholar
• Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164.
   PubMedGoogle Scholar
• Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1302–1306.
   Web of Science ®Google Scholar
• Takayama H, Sato T, Ikeda F, et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus coinfection. Hepatol Res. 2016;46:489–491.
   PubMed Web of Science ®Google Scholar
• Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–136.
   PubMed Web of Science ®Google Scholar
• Yeh M-L, Huang C-F, Hsieh M-H, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32:1754–1762.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Hyland RH, An D, et al. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21(7):605–609.
   PubMed Web of Science ®Google Scholar
• Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27–36.
   PubMed Web of Science ®Google Scholar
• Perrillo RP. Hepatitis B virus reactivation during direct-acting antiviral treatment of chronic hepatitis C: a hidden danger of an otherwise major success story. Hepatology. 2017;66(1):4–6.
   PubMed Web of Science ®Google Scholar
• Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66(1):13–26.
   PubMed Web of Science ®Google Scholar
• Chen X, Xuan M, Wu D. Study of super-infection of HBV and HCV. Zhonghua Liu Xing Bing Xue Za Zhi. 1999;20:141–143.
   PubMedGoogle Scholar
• Xess A, Kumar M, Minz S, et al. Prevalence of hepatitis B and hepatitis C virus co-infection in chronic liver disease. Indian J Pathol Microbiol. 2001;44:253–255.
   PubMedGoogle Scholar
• Chakravarti A, Verma V, Jain M, et al. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital. Trop Gastr. 2005;26:183–187.
   PubMedGoogle Scholar
• Mekky MA, Nasr AM, Saleh MA, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol. 2013;14(4):143–147.
   PubMed Web of Science ®Google Scholar
• Li W, Zhu Y, Hua Z. Exploration on the association between the pattern of HBV markers and infection of HCV among population. Zhonghua Liu Xing Bing Xue Za Zhi. 1994;15:212–214.
   PubMedGoogle Scholar
• Senturk H, Tahan V, Canbakan B, et al. Clinicopathologic features of dual chronic hepatitis B and C infection: a comparison with single hepatitis B, C and delta infections. Ann Hepatol. 2008;7:52–58.
   PubMed Web of Science ®Google Scholar
• Semnani S, Roshandel G, Abdolahi N, et al. Hepatitis B/C virus coinfection in Iran: a seroepidemiological study. Turk J Gastroenterol. 2007;18:20–22.
   PubMed Web of Science ®Google Scholar
• Tyson GL, Kramer JR, Duan Z, et al. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538–545.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Stroffolini T, Sagnelli C, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: data from a multicenter nationwide survey. Dig Liver Dis. 2016;48(9):1066–1071.
   PubMedGoogle Scholar
• Stroffolini T, Sagnelli E, Gaeta GB, et al. Characteristics of liver cirrhosis in Italy: evidence for a decreasing role of HCV aetiology. Eur J Intern Med. 2017;38:68–72.
   PubMed Web of Science ®Google Scholar
• Stroffolini T, Sagnelli E, Almasio PL, et al. Etiological factors of chronic hepatitis in Italy: a 2014 national survey. Eur J Gastroenterol Hepatol. 2017;29:994–997.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Stroffolini T, Sagnelli C, et al. Influence of universal HBV vaccination on chronic HBV infection in Italy: results of a cross-sectional multicentre study. J Med Virol. 2017;89:2138–2143.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Iñigo E, Bartolomé J, Ortiz-Movilla N, et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol. 2005;79:15578–15581.
   PubMed Web of Science ®Google Scholar
• Pasquinelli C, Shoenberger JM, Chung J, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology. 1997;25:719–727.
   PubMed Web of Science ®Google Scholar
• Chen S-Y, Kao C-F, Chen C-M, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278:591–607.
   PubMed Web of Science ®Google Scholar
• Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009;50:46–55.
   PubMed Web of Science ®Google Scholar
• Zoulim F. Does occult HBV infection have an impact on the evolution of chronic hepatitis C? J Hepatol. 2013;59:646–647.
   PubMed Web of Science ®Google Scholar
• Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28:27–33.
   PubMed Web of Science ®Google Scholar
• Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38–41.
   PubMed Web of Science ®Google Scholar
• Schüttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002;37:855–862.
   PubMed Web of Science ®Google Scholar
• Guo H, Zhou T, Jiang D, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol. 2007;81:10072–10080.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wei W, Kang L, et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem Biophys Res Commun. 2007;359:70–75.
   PubMed Web of Science ®Google Scholar
• Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol. 2009;51:446–457.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist. J Hepatol. 2008;49:677–679.
   PubMed Web of Science ®Google Scholar
• Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–1533.
   PubMed Web of Science ®Google Scholar
• Ohkawa K, Hayashi N, Yuki N, et al. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol. 1995;46:258–264.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Ko S, Wong SS, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011;53:1839–1845.
   PubMed Web of Science ®Google Scholar
• Wiegand SB, Jaroszewicz J, Potthoff A, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect. 2015;21(7):710.e1–710.e9. PII:S1198-743X(15)00367-5.
   Google Scholar
• Sato S, Fujiyama S, Tanaka M, et al. Co-infection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol. 1994;21:159–166.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F. Hepatitis C virus super-infection in patients with chronic hepatitis B virus infection. J Gastroenterol. 2002;37(Suppl. 13):65–68.
   PubMed Web of Science ®Google Scholar
• Brotman B, Prince AM, Huima T, et al. Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. J Med Virol. 1983;11:191–205.
   PubMed Web of Science ®Google Scholar
• Sheen I-S, Liaw Y-F, Chu C-M, et al. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992;165:831–834.
   PubMed Web of Science ®Google Scholar
• Bradley DW, Maynard JE, McCaustland KA, et al. Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections. J Med Virol. 1983;11:207–213.
   PubMed Web of Science ®Google Scholar
• Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19(7):859–868.
   PubMed Web of Science ®Google Scholar
• Dustin LB, Trehanpati N. Recent advances in HBV and HCV immunology. Front Immunol. 2015;6:453.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Rodinò G, Smedile V, et al. Hepatitis B virus (HBV) markers and HBV-DNA in serum and liver tissue of patients with acute exacerbation of chronic type B hepatitis. J Hepatol. 1990;10:271–273.
   PubMed Web of Science ®Google Scholar
• Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230–235.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Schneider R, Stemler M, et al. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology. 1990;79:4–68.
   Google Scholar
• Chuang W-L, Dai C-Y, Chang W-Y, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2005;10:125–133.
   PubMed Web of Science ®Google Scholar
• Saitta C, Pontisso P, Brunetto MR, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir Ther. 2006;11:931–934.
   PubMed Web of Science ®Google Scholar
• FDA Draft Guidance for Industry. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. 2016 May. [cited 2016 Apr 20]. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm225333.pdf
   Google Scholar
• IncivekR _ (package insert). Cambridge (MA): Vertex Pharmaceuticals, Inc.; 2013. Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf
   Google Scholar
• Victrelis (package insert). Schering Corporation, a subsidiary of Merck & Co., Inc. Whitehouse Station (NJ): Schering Corporation; 2011. [cited 2011 May].  Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf
   Google Scholar
• SovaldiR _ (package insert). Foster City (CA): Gilead Sciences, Inc.; 2015. Available from: http://www.gilead.com/˜/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
   Google Scholar
• Harvoni (package insert). Foster City (CA): Gilead Sciences, Inc.; 2016. Available from: https://www.gilead.com/˜/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• Olysio (package insert). Titusville (NJ): Janssen Therapeutics; 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205123s010lbl.pdf
   Google Scholar
• Viekira Pak (package insert). North Chicago (IL): AbbVie Inc.; 2016. Available from: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf
   Google Scholar
• Zepatier (package insert). Whitehouse Station (NJ): Merch& Co., Inc.; 2016. Available from: https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
   Google Scholar
• Daklinza(package insert). Princeton (NJ): Bristol-Myers Squibb Company; 2016. Available from: http://packageinserts.bms.com/pi/pi_daklinza.pdf
   Google Scholar
• EpclusaR _ (package insert). Foster City (CA): Gilead Sciences, Inc.; 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label2016/208341s000lbl.pdf
   Google Scholar
• Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ. 1993;307:1095–1097.
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. Clin Infect Dis. 1995;20:703–705.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Chu C-M, Chang-Chien C-S, et al. Simultaneous acute infections with hepatitis non-A, non-B, and B viruses. Dig Dis Sci. 1982;27:762–764.
   PubMed Web of Science ®Google Scholar
• Féray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology. 1993;104:549–555.
   PubMed Web of Science ®Google Scholar
• Coppola N, Marrocco C, Di Caprio D, et al. Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clin Infect Dis. 2003;36:528–532.
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Kobayashi M, et al. Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection. Dig Dis Sci. 2004;49:281–288.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Lin SM, Sheen IS, et al. Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection. 1991;19:250–251.
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Navascués CA, Martínez A, et al. Hepatitis C virus infection in patients with acute hepatitis B. Infection. 1992;20:316–319.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–1097.
   PubMed Web of Science ®Google Scholar
• Jessner W, Strasser M, Graziadei I, et al. Sustained remission of chronic hepatitis C after acute hepatitis B superinfection. Scand J Infect Dis. 2006;38:818–821.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsukuma H, Yamano H, et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer. 2004;112:1075–1080.
   PubMed Web of Science ®Google Scholar
• Cho LY, Yang JJ, Ko K-P, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–184.
   PubMed Web of Science ®Google Scholar
• European Association for The Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut. 2014;63:380–381.
   PubMed Web of Science ®Google Scholar
• Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2:39–45.
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of allcause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–516.e1.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol. 2017 Aug;67(2):370–398. DOI:10.1016/j.jhep.2017.03.021
   Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. J Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Chan HL, Ahn SH, Chang TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J Hepatol. 2016 May;64(5):1011–1019. DOI:10.1016/j.jhep.2015.12.018
   Google Scholar
• Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology. 2014. DOI:10.1002/hep.27323
   PubMed Web of Science ®Google Scholar
• Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–1073.
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Stroffolini T, Mele A, et al. Chronic hepatitis B in Italy: new features of an old disease–approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008;46(1):110–113.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Sun C-A, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157:674–682.6.
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Fontana RJ, Brown K, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C post orthotopic liver transplant: the randomized GALAXY study. Transpl Int Off J Eur Soc Organ Transpl. 2017;30:196–208.
   PubMed Web of Science ®Google Scholar
• Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49(5):688–694.
   PubMed Web of Science ®Google Scholar
• Liu C-J, Chuang W-L, Lee C-M, et al. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology. 2009;136:496–504.
   PubMed Web of Science ®Google Scholar
• Liu C-J, Chuang W-L, Sheen I-S, et al. Ledipasvir/sofosbuvir for 12 weeks is safe and effective in patients with chronic hepatitis C and hepatitis B coinfection: a phase 3 study in Taiwan. EASL 2017. Abstract PS-098. J Hepatol. 2017;66:S56–S57.
   Web of Science ®Google Scholar
• Coppola N, Stanzione M, Messina V, et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hep. 2012;19:890–896.
   PubMed Web of Science ®Google Scholar
• Potthoff A, Berg T, Wedemeyer H; HEP-NET B/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009;44(12):1487–1490.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Sherman KE. Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology. 2009;136(2):393–396.
   PubMed Web of Science ®Google Scholar
• Yu M-L, Lee C-M, Chen C-L, et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology. 2013;57:2135–2142.
   PubMed Web of Science ®Google Scholar
• Yu J-W, Sun L-J, Zhao Y-H, et al. Analysis of the efficacy of treatment with peginterferon a-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver International. 2009;29(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J ClinVirol. 2016;78:27–30.
   Google Scholar
• Hayashi K, Ishigami M, Ishizu Y, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9:252–256.
   PubMed Web of Science ®Google Scholar
• Sato K, Kobayashi T, Yamazaki Y, et al. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatol Res. 2017. DOI:10.1111/hepr.12905
   Web of Science ®Google Scholar
• Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Annals of Internal Medicine. 2017;166(11):792–798.
   Google Scholar
• Sulkowski MS, Chuang W-L, Kao J-H, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202–1204.
   PubMed Web of Science ®Google Scholar
• Macera M, Stanzione M, Messina V, et al. Interferon-free regimens in hepatitis B surface antigen/anti-hepatitis C virus positive patients: the need to control hepatitis B virus replication to avoid hepatitis B virus reactivation. Clin Gastroenterol Hepatol. 2017 May 26;15:1800–1802. PII:S1542-3565(17)30612-2.
   PubMed Web of Science ®Google Scholar